Search

Your search keyword '"Lin, Jia-Ren"' showing total 332 results

Search Constraints

Start Over You searched for: Author "Lin, Jia-Ren" Remove constraint Author: "Lin, Jia-Ren"
332 results on '"Lin, Jia-Ren"'

Search Results

2. AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution

3. Qualification of a multiplexed tissue imaging assay and detection of novel patterns of HER2 heterogeneity in breast cancer

4. Ovarian cancer-derived IL-4 promotes immunotherapy resistance

5. Skin immune-mesenchymal interplay within tertiary lymphoid structures promotes autoimmune pathogenesis in hidradenitis suppurativa

6. A human breast atlas integrating single-cell proteomics and transcriptomics

7. Scope2Screen: Focus+Context Techniques for Pathology Tumor Assessment in Multivariate Image Data

8. MITI Minimum Information guidelines for highly multiplexed tissue images

13. MITI minimum information guidelines for highly multiplexed tissue images

14. MCMICRO: a scalable, modular image-processing pipeline for multiplexed tissue imaging

15. Temporal and spatial topography of cell proliferation in cancer

16. Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma

17. Spatial Profiling of Metals through Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Imaging

19. The Library of Integrated Network-Based Cellular Signatures NIH Program: System-Level Cataloging of Human Cells Response to Perturbations

20. Evolution of delayed resistance to immunotherapy in a melanoma responder

21. The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution

22. Supplementary Table 4 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

23. Supplementary Figure 2 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

24. Supplementary Table 1 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

25. Supplementary Figure 1 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

26. Data from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

27. Supplementary Material 1 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

28. Supplementary Table 3 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

29. Supplementary Table 2 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

30. Abstract B075: Spatial genomics identifies cancer cell cytokines regulating ovarian cancer immunity

31. Immune Profiling of Dermatologic Adverse Events from Checkpoint Blockade using Tissue Cyclic Immunofluorescence: A Pilot Study

32. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer

33. A single-cell landscape of high-grade serous ovarian cancer

34. Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates

36. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

39. Supplementary Tables S2-13 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

40. Figure 4 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

41. Figure 7 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

42. Supplementary Fig. S2 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

43. Figure 6 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

44. Figure 2 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

45. Supplementary Table S1 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

46. Data from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

47. Figure 5 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

48. Figure 1 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

49. Figure 3 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

50. Longitudinal and multimodal auditing of tumor adaptation to CDK4/6 inhibitors in HR+ metastatic breast cancers

Catalog

Books, media, physical & digital resources